MARKET

MYOK

MyoKardia
MYOK
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-36.4510
784.26
14.19
11,992,854,338.64
News
Financial
Releases
Corp Actions
Analysis
Profile
Bristol Myers completes acquisition of MyoKardia
Bristol Myers Squibb (BMY) has successfully completed its acquisition of MyoKardia (MYOK) in an all cash transaction for ~$13.1B.With the completion of the acquisition, MyoKardia shares have ceased trading on
Seekingalpha · 11/17 14:04
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17 13:31
MyoKardia Presents Cardiac Imaging Data from 30-Week EXPLORER-HCM Study of Mavacamten
EXPLORER-HCM Cardiac Imaging Data Presented at AHA 2020 Scientific Session with Simultaneous Publication in Circulation Mavacamten Treatment Resulted in Favorable Effect on Cardiac Structure \-- Significantly Reduced Hypertrophy in Patients with Hypertrophic CardiomyopathyBRISBANE, Calif., Nov. 15, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) announced results from its cardiac magnetic resonance imaging (CMR) substudy of mavacamten for the potential treatment of hypertrophic cardiomyopathy (HCM) showing that 30-week treatment with mavacamten has a favorable effect on cardiac structure, while maintaining contractile function within the normal range. These data were shared today in an oral presentation titled, “Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM CMR substudy” (Oral Session 18654), at the American Heart Association’s Scientific Sessions 2020 during the High Profile Clinical Science in CVD session. Data from the EXPLORER-HCM CMR substudy were also published simultaneously in Circulation.The CMR substudy was conducted as part of MyoKardia’s pivotal Phase 3 EXPLORER-HCM clinical trial in patients with symptomatic, obstructive HCM to assess the impact of once-daily treatment with mavacamten on parameters of cardiac structure and function. Thirty-five patients were enrolled in the CMR substudy and randomized to mavacamten (n=17) or placebo (n=18) and had valid CMR assessments at day 1 and week 30 (end of treatment) which were analyzed centrally in a blinded manner. Statistically significant changes from baseline to Week 30 were observed in the mavacamten group vs. placebo for the primary endpoint of left ventricular mass index (p<0.0001), as well as exploratory endpoints of absolute intracellular myocardial mass index, maximum wall thickness, and maximum left atrial volume index (all p<0.001 for the difference from placebo). From baseline to Week 30, there was no worsening in myocardial fibrosis, another common characteristic of HCM.“Hypertrophic cardiomyopathy is defined by the thickening of the heart muscle, so to see favorable remodeling of the heart indicating a lessening of hypertrophy within 30-weeks of treatment is a highly encouraging finding for the many patients struggling with HCM,” said Sara Saberi, M.D., Assistant Professor in the Division of Cardiovascular Medicine and member of the Inherited Cardiomyopathy Program at the University of Michigan Medical School, and lead author on the study. “The CMR substudy is the first randomized, controlled clinical trial of HCM patients to show that a once-daily oral therapeutic agent can reduce left ventricular wall thickness and mass, and positively impact several other parameters of cardiac structure and function. Left ventricular hypertrophy and left atrial volumes in particular are predictive of poor prognosis in HCM patients, so it will be exciting to see how mavacamten impacts cardiac function and disease progression as we continue to follow patients over time.”  Changes in left ventricular hypertrophy and left atrial volumes were observed concurrently with reductions in levels of plasma biomarkers of myocardial stress and injury, consistent with echocardiographic observations from the overall EXPLORER-HCM population. Importantly, the reduction in left ventricular mass index correlated with a reduction in high-sensitivity cardiac troponin I.  “Data from the CMR substudy complements and extends our observations of mavacamten’s positive benefits on cardiac function and symptom relief, providing us with encouraging evidence that mavacamten treatment may change the course of the adverse cardiac remodeling inherent to HCM. In directly targeting the proteins of the heart muscle that lead to the excessive contraction and impaired relaxation underlying HCM, we have a growing body of data showing that mavacamten is reducing hypercontractility and hypertrophy and reducing harm to the cardiac muscle while maintaining contractile function within the normal range,” said Jay Edelberg, M.D., Ph.D., MyoKardia’s Chief Medical Officer.  As previously reported, results from EXPLORER-HCM demonstrated that patients treated with mavacamten experienced statistically significant and clinically meaningful improvements in symptoms, functional status and key aspects of quality of life. In addition to meeting the primary and all secondary endpoints, mavacamten was well tolerated with a safety profile similar to placebo. MyoKardia plans to submit a New Drug Application for mavacamten to the U.S. Food and Drug Administration (FDA) in the first quarter of 2021.About EXPLORER-HCM The EXPLORER-HCM Phase 3 trial enrolled a total of 251 patients with symptomatic (NYHA Class II or III), obstructive hypertrophic cardiomyopathy. All participants had measurable LVOT gradient (resting and/or provoked) ≥50 mmHg at baseline. Patients were randomized on a 1:1 basis to receive individualized once-daily dosing of mavacamten or placebo. Patients started on a dose of 5mg, with up to two opportunities for dose adjustments (to doses of 2.5mg – 15mg) based on a combination of residual LVOT gradient, drug plasma concentration and left ventricular ejection fraction (LVEF) levels.The primary endpoint for EXPLORER-HCM was a composite functional analysis designed to capture mavacamten’s effect on both symptoms and function. The composite functional endpoint is defined by either (1) the achievement of a ≥1.5mL/kg/min improvement in peak VO2 accompanied by an improvement of ≥1 NYHA functional class, or (2) the achievement of a ≥3.0mL/kg/min improvement of peak VO2 with no worsening in NYHA functional class. In addition to the endpoints reported today, the EXPLORER-HCM study also assessed mavacamten’s effect on patient-reported outcomes, health-related quality-of-life and symptom severity assessments, changes from baseline to Week 30 in echocardiographic indices, circulating biomarkers, cardiac rhythm patterns and accelerometry.About MyoKardia MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic benefit and future potential of mavacamten, the ability of our long-term studies to provide further evidence of how mavacamten impacts cardiac function and disease progression over time, the ability of our long-term studies to provide further evidence of mavacamten’s potential to positively impact several other parameters of cardiac structure and function, that mavacamten treatment may change the course of the adverse cardiac remodeling inherent to HCM, and mavacamten’s ability to reduce harm to the cardiac muscle while maintaining contractile function within the normal range, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates and any ongoing effects of the COVID-19 pandemic, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.comHannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.comJulie Normant (media) W2O 628-213-3754 jnormart@w2ogroup.com
GlobeNewswire · 11/15 21:30
MyoKardia Highlights Presentation Of Mavacamten Clinical, Non-Clinical Data At American Heart Association Sessions
MyoKardia, Inc. (NASDAQ:MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic
Benzinga · 11/13 15:02
MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with Markers of HCM Severity in Non-Obstructive HCMNon-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertrophic cardiomyopathy (HCM), at the American Heart Association’s Scientific Sessions 2020. Three poster presentations were made available detailing exploratory analyses from Myokardia’s Phase 3 EXPLORER-HCM study of mavacamten for the treatment of obstructive HCM and from the Phase 2 MAVERICK-HCM study of mavacamten in patients with non-obstructive HCM, as well as non-clinical results of a mavacamten surrogate compound in a large animal model.“These data add detail to the emerging picture of mavacamten’s beneficial impact on the HCM heart, including improvements in cardiac pathophysiology, diastolic function and biomarkers of disease progression,” said Jay Edelberg, M.D., Ph.D., MyoKardia’s Chief Medical Officer. “HCM is characterized by the thickening of the heart muscle and constraints on diastolic filling. Having repeatedly demonstrated that mavacamten can have a profound effect on reducing the obstruction of the left ventricular outflow tract in HCM, echocardiography data from our EXPLORER-HCM trial show that in just 30 weeks of treatment, mavacamten is gradually bringing measures of cardiac structure closer to a normal state, improving parameters of diastolic function and reducing biomarkers of disease. We are optimistic that these changes may ultimately point to the benefits of mavacamten treatment in the progression of HCM.”Mavacamten Favorably Impacts Key Pathophysiologic Processes in Obstructive Hypertrophic Cardiomyopathy: Results From the EXPLORER-HCM StudyAn exploratory analysis from the Phase 3 EXPLORER-HCM clinical trial of mavacamten for the potential treatment of symptomatic, obstructive HCM investigated the changes from baseline to Week 30 on specific measures of the heart’s structure and function using serial echocardiograms (ultrasounds of the heart). * Treatment with mavacamten led to statistically significant reductions in left ventricular mass (LVMI), indicating that mavacamten is having an effect on cardiac structure. LVMI has been shown to be a predictor of HCM-related mortality. * Mavacamten treatment improved left ventricular relaxation (which in turn led to improved cardiac filling pressures). Statistically significant improvements (p<0.0001 for difference from placebo) were achieved across diverse echocardiographic measurements of diastolic function (LA volume index, lateral e’, lateral E/e’, septal e’, and septal E/e’). * Significantly more mavacamten-treated patients achieved resolution of mitral valve systolic anterior motion (SAM) compared to placebo (80.9% vs. 34.0%; p<0.0001), and 9% achieved resolution of mitral regurgitation (MR) in the mavacamten group vs. none in placebo (p=0.0006). SAM and MR may cause or contribute to obstruction of the left ventricular outflow tract and are known to impact cardiac performance and increase risk of serious cardiovascular complications, such as arrhythmias. * Mavacamten treatment resulted in significant reductions in cardiac biomarkers of myocardial wall stress and injury compared to placebo. Specifically, there was an 80% greater reduction in NT-proBNP and a 41% greater reduction in cardiac troponin in the mavacamten treatment group vs. placebo. * Patients with the highest degree of obstruction at baseline achieved greater improvements in echocardiographic parameters and biomarker reductions. Accelerometer-measured Activity in Non-obstructive Hypertrophic Cardiomyopathy: Patient-generated Activity Measures Correlate With, and are Convolutional Neural Network Predictors of, Clinical Parameters in the MAVERICK-HCM StudyMyoKardia’s Phase 2 MAVERICK-HCM study of mavacamten was the first study to examine quantitative levels of activity in a non-obstructive HCM patient population. As part of the MAVERICK-HCM study, patients were asked to wear ActiGraph GT9X Link wrist-worn monitors for up to 14 days between screening and day 1 and between weeks 12 and 16 to record daily activity. A multitask convolutional neural network (CNN) trained on raw accelerometry, was also used to jointly predict clinical markers of HCM severity.Markers of physical activity drawn from accelerometry, including average daily accelerometer units (ADAUs) and step count, were associated with standard clinical markers of HCM severity. Out the 59 patients enrolled in MAVERICK-HCM, 50 patients wore the accelerometer for ≥1 compliant day. Patients in MAVERICK-HCM averaged 3,000 steps per day. Results from the accelerometry exploratory analyses showed that higher physical activity correlated with key clinical markers of HCM, including exercise capacity as measured by peak VO2, changes in NT-proBNP levels, and improvements in patient reported outcomes using the Kansas City Cardiomyopathy Questionnaire (KCCQ), indicating that accelerometry measures may be a useful indicator of drug activity. CNN predictions of clinical measures from activity data found strong correlations for pVO2, NT-proBNP, KCCQ score, and E over e prime. These findings indicate that deep learning models can be constructed to predict markers of HCM severity from patients’ raw accelerometry data.Chronic Treatment With A Mavacamten-like Myosin-modulator (MYK-581) Prevents Left-atrial Remodeling, Decreases Cardiac Troponin Leakage, And Blunts Mortality In A Mini-pig Model Of Inherited Hypertrophic CardiomyopathyResults from an in vivo study in a genetic mini-pig model of HCM showed that chronic administration of a mavacamten-like myosin-modulator blunted chronic cardiac troponin-T leakage and decreased mortality, both characteristic of HCM progression in this non-obstructive model. In addition, chronic treatment also reduced left-ventricular and prevented left-atrial remodeling, preserving normal left-atrial size as well as atrial myofibrillar structure and function. Taken together, these non-clinical observations provide additional evidence of mavacamten’s activity beyond the reduction of LVOT obstruction and support the emerging clinical evidence of mavacamten’s beneficial effects on overall cardiac structure in the HCM heart.About MyoKardiaMyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the biomechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224.MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.Forward-Looking Statements Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the clinical and therapeutic benefit and future potential of mavacamten, the ability of our long-term studies to provide further evidence of mavacamten’s potential to alter the course of disease by gradually brining measures of cardiac structure to a normal state, usefulness of raw accelerometry data to predict markers of HCM severity in patients, and the ability of non-clinical observations to provide additional evidence of mavacamten’s activity beyond the reduction of LVOT obstruction, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the development and regulation of our product candidates and any ongoing effects of the COVID-19 pandemic, as well as those set forth in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and our other filings with the SEC. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts Michelle Corral Executive Director, Corporate Communications and Investor Relations MyoKardia, Inc. 650-351-4690 ir@myokardia.comHannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.comJulie Normant (media) W2O 628-213-3754 jnormart@w2ogroup.com
GlobeNewswire · 11/13 15:00
The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12)
Benzinga · 11/13 12:40
The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 5)
Benzinga · 11/06 12:47
MyoKardia Q3 EPS $(1.60) Up From $(3.07) YoY
MyoKardia (NASDAQ:MYOK) reported quarterly losses of $(1.60) per share. This is a 47.88 percent increase over losses of $(3.07) per share from the same period last year.
Benzinga · 11/05 21:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MYOK. Analyze the recent business situations of MyoKardia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MYOK stock price target is 214.80 with a high estimate of 225.00 and a low estimate of 123.00.
EPS
Institutional Holdings
Institutions: 336
Institutional Holdings: 61.04M
% Owned: 114.47%
Shares Outstanding: 53.32M
TypeInstitutionsShares
Increased
78
5.03M
New
83
-677.82K
Decreased
76
2.80M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Non-Executive Chairman/Independent Director
Mark Perry
President/Chief Executive Officer/Director
Tassos Gianakakos
Chief Financial Officer
Taylor Harris
Executive Vice President
William Fairey
Chief Scientific Officer
Robert McDowell
General Counsel/Secretary
Denelle Waynick
Other
Jake Bauer
Independent Director
Sunil Agarwal
General Counsel
Cynthia J. Ladd
Independent Director
Mary Cranston
Independent Director
David Meeker
Independent Director
Kimberly Popovits
Independent Director
Wendy Yarno
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of MyoKardia stock information, including NASDAQ:MYOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYOK stock methods without spending real money on the virtual paper trading platform.